Huihong Liang¹, Zhenwei Peng², Liangqi Cao¹, Shikun Qian¹, Zili Shao^1*

Show more
¹ Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
² Department of Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Show less

Abstract: Background: Retrospective comparison of stent patency and survival of patients with unresectable extrahepatic cholangiocarcinoma (CCA) treated by placement of self-expanding metal stents (SEMS) with or without endobiliary radiofrequency ablation (ERFA). Methods: Between January 2010 and September 2014, 76 patients with biliary obstruction caused by unresectable extrahepatic CCA (27 patients with Bismuth type I hilar CCA and 49 patients with distal CCA) were recruited into this study. Patients either received ERFA with SEMS (n = 34) or SEMS only (n = 42). Stent patency and survival of both groups were compared and predictors for overall survival were analyzed. Results: Demographic data were not different between the two groups. Complication rates of both groups were similar. Thirty-day stent patency was obtained in all patients and the median stent patency in the ERFA + SEMS group (9.5 months, 4.5 - 14.0 months) was significantly longer than that in the SEMS group (8.4 months, 4.9 - 11 months) (P = 0.024). The overall survival curve in the ERFA + SEMS group was significantly better than that of the SEMS group (P = 0.036). Multivariate Cox proportional hazards regression analyses showed that ERFA, tumor AJCC stage, extrahepatic CCA type, serum albumin and adjuvant chemotherapy were significant prognostic factors for overall patient survival. Conclusions: ERFA is effective for unresectable extrahepatic CCA and may improve metal stent patency and patient survival for unresectable extrahepatic CCA with biliary obstruction. Prospective randomized trials will be needed to confirm these findings.

Keywords: Cholangiocarcinoma, Endoscopic Retrograde Cholangiopancreatography, Percutaneous Transhepatic Cholangiography, Radiofrequency Ablation, Survival

Cite this paper: Liang, H. , Peng, Z. , Cao, L. , Qian, S. and Shao, Z. (2015) Metal Stenting with or without Endobiliary Radiofrequency Ablation for Unresectable Extrahepatic Cholangiocarcinoma. Journal of Cancer Therapy, 6, 981-992. doi: 10.4236/jct.2015.611106.

References

[1]   Akamatsu, N., Sugawara, Y. and Hashimoto, D. (2011) Surgical Strategy for Bile Duct Cancer: Advances and Current Limitations. World Journal of Clinical Oncology, 2, 94.
http://dx.doi.org/10.5306/wjco.v2.i2.94

[2]   Aljiffry, M., Walsh, M.J. and Molinari, M. (2009) Advances in Diagnosis, Treatment and Palliation of Cholangiocarcinoma: 1990-2009. World Journal of Gastroenterology, 15, 4240-4262.
http://dx.doi.org/10.3748/wjg.15.4240

[3]   Andersen, J.R., Sorensen, S.M., Kruse, A., Rokkjaer, M. and Matzen, P. (1989) Randomised Trial of Endoscopic Endoprosthesis versus Operative Bypass in Malignant Obstructive Jaundice. Gut, 30, 1132-1135.
http://dx.doi.org/10.1136/gut.30.8.1132

[4]   Goenka, M.K. and Goenka, U. (2014) Palliation: Hilar Cholangiocarcinoma. World Journal of Hepatology, 6, 559-569.

[5]   Moss, A.C., Morris, E., Leyden, J. and MacMathuna, P. (2007) Do the Benefits of Metal Stents Justify the Costs? A Systematic Review and Meta-Analysis of Trials Comparing Endoscopic Stents for Malignant Biliary Obstruction. European Journal of Gastroenterology & Hepatology, 19, 1119-1124.
http://dx.doi.org/10.1097/MEG.0b013e3282f16206

[6]   Schmassmann, A., von Gunten, E., Knuchel, J., Scheurer, U., Fehr, H.F. and Halter, F. (1996) Wallstents versus Plastic Stents in Malignant Biliary Obstruction: Effects of Stent Patency of the First and Second Stent on Patient Compliance and Survival. The American Journal of Gastroenterology, 91, 654-659.

[7]   Yoon, W.J., Ryu, J.K., Yang, K.Y., Paik, W.H., Lee, J.K., Woo, S.M., Park, J.K., Kim, Y.T. and Yoon, Y.B. (2009) A Comparison of Metal and Plastic Stents for the Relief of Jaundice in Unresectable Malignant Biliary Obstruction in Korea: An Emphasis on Cost-Effectiveness in a Country with a low ERCP Cost. Gastrointestinal Endoscopy, 70, 284-289.
http://dx.doi.org/10.1016/j.gie.2008.12.241

[8]   Raju, R.P., Jaganmohan, S.R., Ross, W.A., Davila, M.L., Javle, M., Raju, G.S. and Lee, J.H. (2011) Optimum Palliation of Inoperable Hilar Cholangiocarcinoma: Comparative Assessment of the Efficacy of Plastic and Self-Expanding Metal Stents. Digestive Diseases and Sciences, 56, 1557-1564.
http://dx.doi.org/10.1007/s10620-010-1550-5

[9]   Loew, B.J., Howell, D.A., Sanders, M.K., Desilets, D.J., Kortan, P.P., May, G.R., Shah, R.J., Chen, Y.K., Parsons, W.G., Hawes, R.H., Cotton, P.B., Slivka, A.A., Ahmad, J., Lehman, G.A., Sherman, S., Neuhaus, H. and Schumacher, B.M. (2009) Comparative Performance of Uncoated, Self-Expanding Metal Biliary Stents of Different Designs in 2 Diameters: Final Results of an International Multicenter, Randomized, Controlled Trial. Gastrointestinal Endoscopy, 70, 445-453.
http://dx.doi.org/10.1016/j.gie.2008.11.018

[10]   Isayama, H., Komatsu, Y., Tsujino, T., Sasahira, N., Hirano, K., Toda, N., Nakai, Y., Yamamoto, N., Tada, M., Yoshida, H., Shiratori, Y., Kawabe, T. and Omata, M. (2004) A Prospective Randomised Study of “Covered” versus “Uncovered” Diamond Stents for the Management of Distal Malignant Biliary Obstruction. Gut, 53, 729-734.
http://dx.doi.org/10.1136/gut.2003.018945

[11]   Zoepf, T., Jakobs, R., Arnold, J.C., Apel, D. and Riemann, J.F. (2005) Palliation of Nonresectable Bile Duct Cancer: Improved Survival after Photodynamic Therapy. The American Journal of Gastroenterology, 100, 2426-2430.
http://dx.doi.org/10.1111/j.1572-0241.2005.00318.x

[12]   Ortner, M.E., Caca, K., Berr, F., Liebetruth, J., Mansmann, U., Huster, D., Voderholzer, W., Schachschal, G., Mossner, J. and Lochs, H. (2003) Successful Photodynamic Therapy for Nonresectable Cholangiocarcinoma: A Randomized Prospective Study. Gastroenterology, 125, 1355-1363.
http://dx.doi.org/10.1016/j.gastro.2003.07.015

[13]   Tal, A.O., Vermehren, J., Friedrich-Rust, M., Bojunga, J., Sarrazin, C., Zeuzem, S., Trojan, J. and Albert, J.G. (2014) Intraductal Endoscopic Radiofrequency Ablation for the Treatment of Hilar Non-Resectable Malignant Bile Duct Obstruction. World Journal of Gastrointestinal Endoscopy, 6, 13-19.
http://dx.doi.org/10.4253/wjge.v6.i1.13

[14]   Alis, H., Sengoz, C., Gonenc, M., Kalayci, M.U. and Kocatas, A. (2013) Endobiliary Radiofrequency Ablation for Malignant Biliary Obstruction. Hepatobiliary & Pancreatic Diseases International, 12, 423-427.
http://dx.doi.org/10.1016/S1499-3872(13)60066-1

[15]   Strand, D.S., Cosgrove, N.D., Patrie, J.T., Cox, D.G., Bauer, T.W., Adams, R.B., Mann, J.A., Sauer, B.G., Shami, V.M. and Wang, A.Y. (2014) ERCP-Directed Radiofrequency Ablation and Photodynamic Therapy Are Associated with Comparable Survival in the Treatment of Unresectable Cholangiocarcinoma. Gastrointestinal Endoscopy, 80, 794-804.
http://dx.doi.org/10.1016/j.gie.2014.02.1030

[16]   Rustagi, T. and Jamidar, P.A. (2014) Intraductal Radiofrequency Ablation for Management of Malignant Biliary Obstruction. Digestive Diseases and Sciences, 59, 2635-2641.
http://dx.doi.org/10.1007/s10620-014-3237-9

[17]   Steel, A.W., Postgate, A.J., Khorsandi, S., Nicholls, J., Jiao, L., Vlavianos, P., Habib, N. and Westaby, D. (2011) Endoscopically Applied Radiofrequency Ablation Appears to Be Safe in the Treatment of Malignant Biliary Obstruction. Gastrointestinal Endoscopy, 73, 149-153.
http://dx.doi.org/10.1016/j.gie.2010.09.031

[18]   Wadsworth, C.A., Westaby, D. and Khan, S.A. (2013) Endoscopic Radiofrequency Ablation for Cholangiocarcinoma. Current Opinion in Gastroenterology, 29, 305-311.
http://dx.doi.org/10.1097/MOG.0b013e32835faacc

[19]   Figueroa-Barojas, P., Bakhru, M.R., Habib, N.A., Ellen, K., Millman, J., Jamal-Kabani, A., Gaidhane, M. and Kahaleh, M. (2013) Safety and Efficacy of Radiofrequency Ablation in the Management of Unresectable Bile Duct and Pancreatic Cancer: A Novel Palliation Technique. Journal of Oncology, 2013, 1-5.
http://dx.doi.org/10.1155/2013/910897

[20]   National Comprehensive Cancer Network (2010) NCCN Clinical Practice Guidelines in Oncology: Hepatiobiliary Cancers, V.1.2010.
http://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf

[21]   Dindo, D., Demartines, N. and Clavien, P.A. (2004) Classification of Surgical Complications: A New Proposal with Evaluation in a Cohort of 6336 Patients and Results of a Survey. Annals of Surgery, 240, 205-213.
http://dx.doi.org/10.1097/01.sla.0000133083.54934.ae

[22]   Goldberg, S.N., Hahn, P.F., Tanabe, K.K., Mueller, P.R., Schima, W., Athanasoulis, C.A., Compton, C.C., Solbiati, L. and Gazelle, G.S. (1998) Percutaneous Radiofrequency Tissue Ablation: Does Perfusion-Mediated Tissue Cooling Limit Coagulation Necrosis? Journal of Vascular and Interventional Radiology, 9, 101-111.
http://dx.doi.org/10.1016/S1051-0443(98)70491-9

[23]   Pai, M., Valek, V., Tomas, A., Doros, A., Quaretti, P., Golfieri, R., Mosconi, C. and Habib, N. (2014) Percutaneous Intraductal Radiofrequency Ablation for Clearance of Occluded Metal Stent in Malignant Biliary Obstruction: Feasibility and Early Results. CardioVascular and Interventional Radiology, 37, 235-240.
http://dx.doi.org/10.1007/s00270-013-0688-x

[24]   Valle, J., Wasan, H., Palmer, D.H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S.P., Roughto, M. and Bridgewater, J. (2010) Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. New England Journal of Medicine, 362, 1273-1281.
http://dx.doi.org/10.1056/NEJMoa0908721